Full Title
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects with Advanced Solid TumorsPurpose
The purpose of this study is to find the highest dose of ABBV-400 to treat advanced cancer. The people in this study have solid tumors that spread (metastasized). In addition, the tumors make too much of a protein called c-MET. High levels of c-MET can cause cancer to grow and spread.
ABBV-400 binds to tumor cells with high levels of c-MET. It is designed to deliver chemotherapy to those cells, stopping tumor growth. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a cancerous solid tumor that has spread.
- Have recovered from the serious side effects of prior therapies before receiving ABBV-400.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call 646-888-4226.
Protocol
23-356
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT05029882